Literature DB >> 26316643

Chemoenzymatic Synthesis, Characterization, and Scale-Up of Milk Thistle Flavonolignan Glucuronides.

Brandon T Gufford1, Tyler N Graf1, Noemi D Paguigan1, Nicholas H Oberlies1, Mary F Paine2.   

Abstract

Plant-based therapeutics, including herbal products, continue to represent a growing facet of the contemporary health care market. Mechanistic descriptions of the pharmacokinetics and pharmacodynamics of constituents composing these products remain nascent, particularly for metabolites produced following herbal product ingestion. Generation and characterization of authentic metabolite standards are essential to improve the quantitative mechanistic understanding of herbal product disposition in both in vitro and in vivo systems. Using the model herbal product, milk thistle, the objective of this work was to biosynthesize multimilligram quantities of glucuronides of select constituents (flavonolignans) to fill multiple knowledge gaps in the understanding of herbal product disposition and action. A partnership between clinical pharmacology and natural products chemistry expertise was leveraged to optimize reaction conditions for efficient glucuronide formation and evaluate alternate enzyme and reagent sources to improve cost effectiveness. Optimized reaction conditions used at least one-fourth the amount of microsomal protein (from bovine liver) and cofactor (UDP glucuronic acid) compared with typical conditions using human-derived subcellular fractions, providing substantial cost savings. Glucuronidation was flavonolignan-dependent. Silybin A, silybin B, isosilybin A, and isosilybin B generated five, four, four, and three monoglucuronides, respectively. Large-scale synthesis (40 mg of starting material) generated three glucuronides of silybin A: silybin A-7-O-β-D-glucuronide (15.7 mg), silybin A-5-O-β-D-glucuronide (1.6 mg), and silybin A-4´´-O-β-D-glucuronide (11.1 mg). This optimized, cost-efficient method lays the foundation for a systematic approach to synthesize and characterize herbal product constituent glucuronides, enabling an improved understanding of mechanisms underlying herbal product disposition and action.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26316643      PMCID: PMC4613946          DOI: 10.1124/dmd.115.066076

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  43 in total

1.  Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.

Authors:  Katherine L Gill; J Brian Houston; Aleksandra Galetin
Journal:  Drug Metab Dispos       Date:  2012-01-24       Impact factor: 3.922

2.  Enzymatic kinetic resolution of silybin diastereoisomers.

Authors:  Daniela Monti; Radek Gazák; Petr Marhol; David Biedermann; Katerina Purchartová; Mirko Fedrigo; Sergio Riva; Vladimír Kren
Journal:  J Nat Prod       Date:  2010-04-23       Impact factor: 4.050

Review 3.  Addressing the challenges of low clearance in drug research.

Authors:  Li Di; R Scott Obach
Journal:  AAPS J       Date:  2015-01-08       Impact factor: 4.009

4.  Biosynthesis of drug metabolites and quantitation using NMR spectroscopy for use in pharmacologic and drug metabolism studies.

Authors:  Gregory S Walker; Jonathan N Bauman; Tim F Ryder; Evan B Smith; Douglas K Spracklin; R Scott Obach
Journal:  Drug Metab Dispos       Date:  2014-07-22       Impact factor: 3.922

5.  Bovine serum albumin decreases Km values of human UDP-glucuronosyltransferases 1A9 and 2B7 and increases Vmax values of UGT1A9.

Authors:  Nenad Manevski; Paolo Svaluto Moreolo; Jari Yli-Kauhaluoma; Moshe Finel
Journal:  Drug Metab Dispos       Date:  2011-08-19       Impact factor: 3.922

6.  Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors.

Authors:  Robert L Walsky; Jonathan N Bauman; Karine Bourcier; Georgina Giddens; Kimberly Lapham; Andre Negahban; Tim F Ryder; R Scott Obach; Ruth Hyland; Theunis C Goosen
Journal:  Drug Metab Dispos       Date:  2012-02-22       Impact factor: 3.922

Review 7.  Pharmacokinetic herb-drug interactions (part 1): origins, mechanisms, and the impact of botanical dietary supplements.

Authors:  Bill J Gurley
Journal:  Planta Med       Date:  2012-02-09       Impact factor: 3.352

8.  Peptaibols from two unidentified fungi of the order Hypocreales with cytotoxic, antibiotic, and anthelmintic activities.

Authors:  Sloan Ayers; Brandie M Ehrmann; Audrey F Adcock; David J Kroll; Esperanza J Carcache de Blanco; Qi Shen; Steven M Swanson; Joseph O Falkinham; Mansukh C Wani; Sheila M Mitchell; Cedric J Pearce; Nicholas H Oberlies
Journal:  J Pept Sci       Date:  2012-06-29       Impact factor: 1.905

Review 9.  Biotransformation of silybin and its congeners.

Authors:  Vladimír Křen; Petr Marhol; Kateřina Purchartová; Eva Gabrielová; Martin Modrianský
Journal:  Curr Drug Metab       Date:  2013-12       Impact factor: 3.731

10.  Albumin stimulates the activity of the human UDP-glucuronosyltransferases 1A7, 1A8, 1A10, 2A1 and 2B15, but the effects are enzyme and substrate dependent.

Authors:  Nenad Manevski; Johanna Troberg; Paolo Svaluto-Moreolo; Klaudyna Dziedzic; Jari Yli-Kauhaluoma; Moshe Finel
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

View more
  1 in total

1.  Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions.

Authors:  Katherine D Lynch; Michelle L Montonye; Dan-Dan Tian; Tarana Arman; Victoria O Oyanna; Baron J Bechtold; Tyler N Graf; Nicholas H Oberlies; Mary F Paine; John D Clarke
Journal:  Phytother Res       Date:  2021-02-15       Impact factor: 6.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.